
Quarterly report 2025-Q3
added 11-05-2025
Align Technology EBITDA 2011-2026 | ALGN
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Align Technology
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 753 M | 786 M | 768 M | 1.09 B | 481 M | 593 M | 521 M | 391 M | 273 M | 207 M | 211 M | 178 M | 126 M | 92.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.09 B | 92.8 M | 462 M |
Quarterly EBITDA Align Technology
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 152 M | 204 M | 170 M | - | 200 M | 183 M | 187 M | - | 203 M | 208 M | 169 M | - | 176 M | 218 M | 228 M | - | 289 M | 295 M | 251 M | - | 202 M | -49.5 M | 90.7 M | - | 147 M | 196 M | 106 M | - | 139 M | 135 M | 110 M | - | 109 M | 92.4 M | 69.5 M | - | 69 M | 70.2 M | 58.1 M | - | 51.2 M | 51 M | 53.2 M | - | 65 M | 57.9 M | 46.6 M | - | 54.1 M | 46.7 M | -33.1 M | - | 17 M | 41.9 M | 30.8 M | - | 35.4 M | 22.7 M | 24 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 295 M | -49.5 M | 116 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | ||
|
AdaptHealth Corp.
AHCO
|
473 M | $ 12.0 | -0.58 % | $ 1.62 B | ||
|
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | ||
|
ClearPoint Neuro
CLPT
|
-23.4 M | $ 9.15 | -2.51 % | $ 259 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | ||
|
Bruker Corporation
BRKR
|
437 M | $ 36.35 | -1.05 % | $ 5.42 K | ||
|
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | ||
|
OrthoPediatrics Corp.
KIDS
|
-18.1 M | $ 15.71 | -1.44 % | $ 369 M | ||
|
EDAP TMS S.A.
EDAP
|
-17.9 M | $ 3.4 | -1.73 % | $ 127 M | ||
|
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
AxoGen
AXGN
|
-1.19 M | $ 31.05 | -4.87 % | $ 1.43 B | ||
|
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
-24.1 M | - | 1.37 % | $ 20.5 M | ||
|
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M | ||
|
Butterfly Network
BFLY
|
-65.5 M | $ 4.01 | -2.91 % | $ 849 M | ||
|
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | ||
|
Cytosorbents Corporation
CTSO
|
-13.5 M | $ 0.61 | 3.37 % | $ 38 M | ||
|
TELA Bio
TELA
|
-33.1 M | $ 0.69 | 9.81 % | $ 32.4 M | ||
|
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
898 K | $ 9.65 | -0.52 % | $ 346 M | ||
|
FONAR Corporation
FONR
|
9.84 M | $ 18.58 | -0.11 % | $ 122 M | ||
|
BioSig Technologies
BSGM
|
-67.6 M | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
4.98 B | $ 61.35 | -1.93 % | $ 90.8 B | ||
|
Alphatec Holdings
ATEC
|
-4.64 M | $ 11.1 | 1.19 % | $ 1.67 B | ||
|
CONMED Corporation
CNMD
|
120 M | $ 34.34 | 0.81 % | $ 1.07 B | ||
|
Globus Medical
GMED
|
757 M | $ 90.53 | 2.15 % | $ 12.2 B | ||
|
Edwards Lifesciences Corporation
EW
|
1.42 B | $ 80.81 | -0.42 % | $ 47.3 B | ||
|
Helius Medical Technologies
HSDT
|
-12.4 M | $ 1.76 | -7.37 % | $ 1.07 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
70.8 M | $ 9.31 | - | $ 717 M | ||
|
Inspire Medical Systems
INSP
|
64.9 M | $ 54.8 | 1.25 % | $ 1.61 B | ||
|
IRIDEX Corporation
IRIX
|
-2.05 M | $ 1.0 | 0.34 % | $ 16.9 M | ||
|
Integer Holdings Corporation
ITGR
|
352 M | $ 85.37 | -0.29 % | $ 2.97 B | ||
|
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | ||
|
LENSAR
LNSR
|
-21 M | $ 5.84 | -0.85 % | $ 69.8 M | ||
|
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
-148 M | - | -10.19 % | $ 1.99 M | ||
|
Medtronic PLC
MDT
|
8.82 B | $ 86.48 | 0.22 % | $ 111 B | ||
|
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
-106 M | - | - | $ 10.2 M | ||
|
Myomo
MYO
|
-13.5 M | $ 0.67 | -4.29 % | $ 28 M | ||
|
Second Sight Medical Products
EYES
|
-27.1 M | - | -0.97 % | $ 54.4 M |